NCT00486538

Study of ABT-869 in Subjects With Advanced Renal Cell Carcinoma Who Have Previously Received Treatment With Sunitinib

An Open-Label, Phase 2 Study to Evaluate the Efficacy and Tolerability of ABT-869 in Subjects With Advanced Renal Cell Carcinoma (RCC) Who Have Previously Received Treatment With Sunitinib

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 53 (actual)
• Sponsor: AbbVie (prior sponsor, Abbott) · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is designed to determine the clinical efficacy and toxicity of ABT 869 in the treatment of subjects with advanced renal cell carcinoma who have previously received treatment with sunitinib.

Conditions

• Advanced Renal Cell Carcinoma

Interventions

Type	Name	Description
DRUG	ABT-869	One oral dose daily.

Timeline

• Start date: 2007-06-01
• Primary completion: 2011-06-01
• Completion: 2012-06-01
• First posted: 2007-06-14
• Last updated: 2013-01-04

Locations

13 sites across 2 countries: United States, Canada